# Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

> **NCT00654732** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Classic Hodgkin Lymphoma
- Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
- Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8

## Interventions

- **DRUG:** Bleomycin
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin Hydrochloride
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vinblastine

## Key facts

- **NCT ID:** NCT00654732
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-19
- **Primary completion:** 2018-09-05
- **Final completion:** 2018-09-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654732, "Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00654732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*